| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Division of Clinical Epidemiology, Royal Victoria Hospital, and Dept of Epidemiology and Biostatistics, McGill University, 3 Institut Cardiologique de Montréal, Université de Montréal, Montréal, Canada, 2 Laboratoire de Santé Publique EA 3279, Université de la Méditerranée, and Dépt d'Oncogénétique, Institut Paoli-Calmettes, Marseille, France
CORRESPONDENCE: S. Suissa, Division of Clinical Epidemiology, Royal Victoria Hospital, 687 Pine Avenue West, Ross 4.29, Montreal, Québec, Canada, H3A 1A1. Fax: 1 5148431493. E-mail: samy.suissa@clinepi.mcgill.ca
Keywords: Acute myocardial infarction, chronic obstructive pulmonary disease, cohort study, databases, inflammation, inhaled corticosteroids
Received: June 30, 2004
Accepted December 13, 2004
 |
ABSTRACT |
|---|
 TOP ABSTRACT METHODSRESULTSDISCUSSIONACKNOWLEDGEMENTSREFERENCES |
|---|
Saskatchewan (Canada) health services databases were used to form a population-based cohort of 5,648 patients, 
55 yrs, who received a first treatment for COPD between 1990 and 1997. A nested case-control analysis was conducted, where 371 cases presenting with a first AMI were matched with 1,864 controls, based on the date of cohort entry and age. A conditional logistic regression was used to estimate the effect of ICS, after adjusting for use of oral corticosteroids, severity of COPD, sex, systemic hypertension, diabetes and cardiovascular disease.
ICS were used in the prior year by 42.2% of cases and 46.4% of controls. Overall, current use of ICS was not associated with a significant decrease in the risk of AMI. However, a 32% reduction in the risk of AMI was observed for doses ranging 50–200 µg·day–1.
In conclusion, very low doses of inhaled corticosteroids may be associated with a reduction in the risk of acute myocardial infarction.
Chronic obstructive pulmonary disease (COPD) is characterised by slowly progressive and, mostly, irreversible airflow limitation 1. Inflammatory changes in the airway and lung parenchyma are considered to be responsible for the decline in lung function. As COPD and asthma share common disease features, and because corticosteroids are effective in treating airway inflammation in asthma, these medications are now widely used in the treatment of COPD 2, 3. Corticosteroids, however, are known to promote hypertension, hyperlipidaemia and glucose intolerance 4–6, well-recognised risk factors for cardiovascular disease. Since the effect of corticosteroids on the cardiovascular system is dose related, the low doses contained in inhaled corticosteroids (ICS) are thought to have few, if any, cardiovascular side-effects.
Inflammation plays a major role in the initiation and progression of coronary atherosclerotic plaque 7 and its complications, such as acute coronary syndromes 8–10. In clinical studies, markers of inflammation, such as C-reactive protein, were found to predict the risk of future myocardial infarction 11, 12. It has, therefore, been suggested that anti-inflammatory agents may prevent cardiovascular disease 13 and that the risk reduction observed with aspirin may also be due to its anti-inflammatory properties in addition to its anti-platelet effect 11. Despite limited systemic side-effects, ICS possess systemic anti-inflammatory properties 14. It is, therefore, possible that ICS might also prevent acute coronary syndromes. Indeed, a recent study showed a protective effect of ICS on the risk of acute myocardial infarction (AMI) in a population of asthma patients 15.
Therefore, in this study, the effect of ICS on the risk of AMI was evaluated in a population-based sample of COPD patients. It was hypothesised that the effect of ICS was dose related, specifically, that a protective effect was attained at doses large enough to have a systemic effect, yet small enough to not induce side-effects.
|
METHODS |
|---|
|
TOPABSTRACTMETHODSRESULTSDISCUSSIONACKNOWLEDGEMENTSREFERENCES |
|---|
1,000,000). Approximately 9% of the population have their drug prescriptions paid by another agency and are, therefore, not eligible for outpatient prescription drug benefits 16. These databases have been used extensively for research, and provide valid information for each individual on prescriptions dispensed, hospital stay, use of physician services and vital status information. The recording of cardiovascular diseases in the hospital separation database has been previously studied and found to be accurate 17. Subjects cannot be identified nor be contacted to obtain supplemental information.
A population-based cohort of new patients with COPD was defined according to the drugs dispensed: to enter the cohort, a minimum of three prescriptions was required, on two different dates, in any 1-yr period, of an inhaled or oral ß2-agonist, xanthine or ipratropium (grouped under the term bronchodilators). The entry date was the time of the third prescription for a bronchodilator between January 1, 1990, and December 31, 1997. Patients 55 yrs at cohort entry, who had not received any bronchodilator, anti-asthma drug (cromolyn, nedocromil or ketotifen), or nasal or ICS in the prior 5 yrs were included. In this way, it was hoped that most patients with new-onset COPD would be included and that subjects with prior asthma would be excluded. Subjects were also required to have been registered in the health plan for at least 5 yrs, in an attempt to exclude patients who had had an AMI in the 5 yrs prior to cohort entry. Subjects were followed until the date of first AMI, December 31, 1999, or the end of coverage (including emigration from the province or death), whichever came first.
Outcome
The outcome of interest was the first, fatal or nonfatal, AMI. Cases were identified using discharge diagnoses from the hospital separation database and underlying causes of death from the vital statistics information 18. The date of first admission for AMI or date of death defined the index date. The recording of AMI in the hospital separation database has been previously studied. Compared to medical charts, diagnostic agreement in the hospital separation database was as high as 97% 17.
Study design
A nested case-control analysis was used within the cohort. This allows one to concentrate attention on exposure to medications in the time period directly leading up to the event of interest, AMI. Cases and all available controls were matched on age (±1 yr), as well as on the date of cohort entry (±6 months), in order to control for trends over time. Controls had to be at risk at the time of the AMI (index date) of the case to which they were matched; that is, controls had to be alive, resident in Saskatchewan, and free of the outcome (AMI).
Exposure
All ICS prescriptions identified from the drug prescription database were converted into beclomethasone-equivalent doses 19. Subjects were considered currently exposed to ICS if they had been dispensed a canister of high-dose beclomethasone or budesonide within 60 days before the index date or a canister of low-dose beclomethasone or budesonide, or other types of ICS, within 30 days before the index date. When more than one canister was dispensed on the same day, the canisters were considered to have been used in successive time periods. Since dosage is not provided in the database, duration of each prescription was estimated based on clinical recommendations and on quantity dispensed. An average daily dose of ICS was calculated by dividing the total mg dispensed in the last 12 months by 365 or by the duration of follow-up in days when the latter was shorter than 1 yr. The average daily dose was then divided into three categories <50 µg, 50–200 µg and >200 µg·day–1. For currently exposed subjects, the duration of continuous exposure was defined as the period when, on average, one canister was filled in every 2-month period and allowing a lag of 1/3 of the prescription duration for the prescription to be refilled. The duration from the end of the last prescription defined how recent use was. Since no information is available on drugs dispensed in hospital, patients were excluded when they had durations of hospitalisation >30 days within 3 months or >90 days within the 12 months prior to index date.
Covariates
The following AMI risk factors were adjusted for: sex, systemic hypertension, diabetes, hyperlipidaemia, cardiovascular disease, defined as present or absent according to either drugs dispensed in the 1-yr period before cohort entry (systemic hypertension, diabetes, hyperlipidaemia) or discharge diagnoses anytime before cohort entry (heart failure) or both (ischaemic heart disease).
Severity of the respiratory disease was controlled for by matching on age and duration of disease, and by adjusting for COPD exacerbations and co-medications as follows: number of prescriptions for inhaled ß2-agonists, xanthines or ipratropium in the prior 12 months, and total number of mg of oral corticosteroids in the prior 12 months (expressed in hydrocortisone-equivalent mg). The number of exacerbations of COPD during follow-up was defined as the number of hospitalisations with COPD as the primary discharge diagnosis and the number of times where, within a 7-day time-window, antibiotics and corticosteroids were simultaneously prescribed.
Statistical analysis
All analyses used techniques for matched data. As the number of controls per case varied in each risk set, descriptive statistics were weighted by the inverse of the number of controls in each matched set. This is equivalent to standardising the number of controls to one control per case. A multivariate conditional logistic regression model was used to calculate odds ratios, equivalent to rate ratios (RR) in the nested case-control analysis, and 95% confidence intervals. The reference category was the absence of ICS use in the 12-month period prior to index date. The model was adjusted for the confounders and covariates that were found to modify the effect. To adjust for severity of COPD, different models were tested. In the final model, assessment of severity was based on the number of prior exacerbations, number of canisters of bronchodilators or prescriptions of nebulised bronchodilators (categorised as 0, 1–12 or >12) in the prior 12 months, and the dose of oral corticosteroids dispensed in the prior 12 months. In order to assess whether oral corticosteroids might be related to AMI in a nonlinear fashion, quadratic splines were included in the conditional logistic regression model. This method splits the covariate range into a few segments, and fits a linear and quadratic term for each of these. A restriction is also added to ensure that the estimated hazard ratios are continuous across segments.
|
RESULTS |
|---|
|
TOPABSTRACTMETHODSRESULTSDISCUSSIONACKNOWLEDGEMENTSREFERENCES |
|---|
.
|
–4 are adjusted for sex, severity of COPD, hospitalisation in the last 3 months, hypertension, diabetes, ischaemic heart disease and heart failure. The adjustment for treated hyperlipidaemia, use of aspirin and other anti-inflammatory agents did not modify the association between ICS use and AMI; therefore, these variables were not included in the final model.
|
|
|
). The current use of ICS was associated with a RR of 0.82 (0.57–1.16). The RR for AMI was <1 for average daily doses of ICS <500 µg and returned to baseline for the larger doses (table 3). The second stratum of average daily dose (50–200 µg) was associated with a significant reduction in the risk of AMI (RR 0.68 (0.47–0.99)). The dose-related effect of ICS is described in a continuous way in figure 1.
|
). However, among current users, the mean duration of medication use was longer in controls than in cases, but not significantly so (table 4). How recently they were used was not associated with AMI risk (data not shown). |
DISCUSSION |
|---|
|
TOPABSTRACTMETHODSRESULTSDISCUSSIONACKNOWLEDGEMENTSREFERENCES |
|---|
The beneficial effects of ICS on the risk of AMI may be explained by the anti-inflammatory effects of ICS. The anti-inflammatory actions of corticosteroids encompass a wide variety of effects that are now considered as central components in the occurrence of AMI. Acute modifications of the atherosclerotic plaque that involve enhanced inflammatory activity within the plaque 7 and, possibly, throughout the entire coronary arteries 20, precipitate AMI. Anti-inflammatory actions of corticosteroids involve the modification of the expression of a wide number of genes, in turn, inhibiting the synthesis of cytokines (interleukin (IL)-2, IL-6, tumour necrosis factor -
, interferon-
), adhesion molecules (intercellular adhesion molecule 1, endothelial leukocyte adhesion molecule 1), enzymes (inducible nitric oxide synthase, cyclooxygenase, collagenase) and other proteins (granulocyte-macrophage colony-stimulating factor) involved in inflammation 21, 22 and implicated in the pathogenesis of acute coronary syndromes 8. Furthermore, the anti-atherogenic properties of corticosteroids have been demonstrated in several animal studies 23–26. The lack of benefit at higher doses might plausibly reflect counterbalancing adverse effects on other risk factors or the fact that patients with more severe disease, itself linked to cardiovascular morbidity, are dispensed higher doses. Recently, Sin et al. 27 were able to show a reduction in C-reactive protein, itself a marker of increase in risk of acute coronary syndromes, with high doses of ICS over a period of several weeks.
Other explanations for the findings presented here are also possible. As discussed by Suissa et al. 15, the observed effect of ICS on the risk of AMI may be due to a better control of the respiratory disease, either by a reduction of the number of acute exacerbations and the associated hypoxia, or by improving airflow limitation in a subgroup of steroid responders. Although ICS are of limited benefit in COPD, a meta-analysis of nine clinical trials showed a 30% reduction in the number of exacerbations in patients treated for >6 months with high-dose ICS 28. The current analysis was adjusted for the number of exacerbations prior to the AMI, as well as for the quantity of bronchodilators and oral corticosteroids dispensed. Therefore, while residual confounding by severity of COPD may exist, the authors believe it is unlikely to explain the findings.
The present study has limitations that should be considered in interpreting the results. First, the doses on which the assessment of the effect of ICS were based are calculated from filled prescriptions. If subjects were taking less than the inferred dose dispensed, the beneficial effect of low doses of ICS on the risk of AMI may have been underestimated. Furthermore, the lack of a protective effect of ICS at higher doses argues against the possibility that the beneficial effect of low-dose ICS might reflect compliant behaviour with regular therapy of a condition, itself associated with better prognosis 29. Secondly, there was the challenge of taking COPD severity into account. Controlling for age, duration of disease, frequency of COPD exacerbations and other dispensed therapy should, however, provide a good measure of COPD severity. Patients on ICS are likely to be more severe 1 and at higher risk for cardiovascular disease 30–32 than patients not receiving this treatment. Confounding by indication is therefore unlikely to explain the observed protective effect for doses ranging 50–200 µg of ICS. However, confounding by indication may mask a protective effect of larger doses of ICS because of possible residual confounding by severity of the lung disease. Further investigation of the dose of corticosteroids that would be of benefit is warranted.
A further limitation of the current study is the absence of information on smoking, an important risk factor for AMI not collected in administrative databases. To confound the association between ICS and AMI, current smoking would have to be associated with the use of ICS, even after adjusting for the number of exacerbations and concomitant respiratory medications.
In conclusion, the results presented here suggest that inhaled corticosteroids may be associated with a reduction in the risk of acute coronary events. This risk reduction was observed for doses of the medication ranging 50–200 µg·day–1 of beclomethasone or the equivalent. However, this therapeutic window may be dependent on the population and study setting. The mechanism of action is still unclear and it cannot be established whether the present results are due strictly to the dose or whether the route of administration may also play an important role. There is a need to further investigate the effect of inhaled corticosteroids on the risk of acute myocardial infarction since inhaled corticosteroids might provide some clinical benefits with few serious side-effects and at reasonable cost.
|
ACKNOWLEDGEMENTS |
|---|
|
TOPABSTRACTMETHODSRESULTSDISCUSSIONACKNOWLEDGEMENTSREFERENCES |
|---|
|
FOOTNOTES |
|---|
|
REFERENCES |
|---|
|
TOPABSTRACTMETHODSRESULTSDISCUSSIONACKNOWLEDGEMENTSREFERENCES |
|---|
This article has been cited by other articles:
|
|
 |
|
  E. S. Mendes, G. Horvath, P. Rebolledo, M. E. Monzon, S. M. Casalino-Matsuda, and A. Wanner Effect of an inhaled glucocorticoid on endothelial function in healthy smokers J Appl Physiol, July 1, 2008; 105(1): 54 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A K Johnston, D M Mannino, G W Hagan, K J Davis, and V A Kiri Relationship between lung function impairment and incidence or recurrence of cardiovascular events in a middle-aged cohort Thorax, July 1, 2008; 63(7): 599 - 605. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. MacNee Update in Chronic Obstructive Pulmonary Disease 2007 Am. J. Respir. Crit. Care Med., April 15, 2008; 177(8): 820 - 829. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Agusti Systemic Effects of Chronic Obstructive Pulmonary Disease: What We Know and What We Don't Know (but Should) Proceedings of the ATS, October 1, 2007; 4(7): 522 - 525. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. F. Rabe Treating COPD -- The TORCH Trial, P Values, and the Dodo N. Engl. J. Med., February 22, 2007; 356(8): 851 - 854. [Full Text] [PDF]
|
|
|
|
 |
|
 V. Soyseth, P. H. Brekke, P. Smith, and T. Omland Statin use is associated with reduced mortality in COPD Eur. Respir. J., February 1, 2007; 29(2): 279 - 283. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. D. Sin and S.F. P. Man Cooling the Fire Within: Inhaled Corticosteroids and Cardiovascular Mortality in COPD. Chest, September 1, 2006; 130(3): 629 - 631. [Full Text] [PDF]
|
|
|
|
|
|
C. Macie, K. Wooldrage, J. Manfreda, and N. R. Anthonisen Inhaled Corticosteroids and Mortality in COPD. Chest, September 1, 2006; 130(3): 640 - 646. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. D. Sin and S. F. P. Man Pharmacotherapy for Mortality Reduction in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, September 1, 2006; 3(7): 624 - 629. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Agusti Thomas A. Neff Lecture. Chronic Obstructive Pulmonary Disease: A Systemic Disease Proceedings of the ATS, August 1, 2006; 3(6): 478 - 481. [Full Text] [PDF]
|
|
|
|
|
|
W. MacNee Conference Summary Proceedings of the ATS, August 1, 2006; 3(6): 539 - 542. [Full Text] [PDF]
|
|
|
|
|
|
A. G. N. Agusti Systemic Effects of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, November 1, 2005; 2(4): 367 - 370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. A. Kiri, N. B. Pride, J. B. Soriano, and J. Vestbo Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease: Results from Two Observational Designs Free of Immortal Time Bias Am. J. Respir. Crit. Care Med., August 15, 2005; 172(4): 460 - 464. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. D. Sin and S. F. P. Man Can inhaled steroids mend a broken heart in chronic obstructive pulmonary disease? Eur. Respir. J., April 1, 2005; 25(4): 589 - 590. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
